BioCardia (BCDA) Price to Sales (2016 - 2024)

BioCardia (BCDA) has reported Price to Sales for 9 consecutive years, with 2102.64 the latest figure, recorded in Q2 2024.

• On a quarterly basis, Price to Sales rose 56.86% year-over-year to 2102.64 in Q2 2024; TTM through Mar 2025 was 3964.25, a 16760.76% increase from a year earlier, with the FY2024 full-year figure at 103.13, up 214.92% from the prior year.
• Price to Sales was 2102.64 for Q2 2024 at BioCardia, up from 200.06 in the prior quarter.
• Over five years, Price to Sales peaked at 2102.64 in Q2 2024 and troughed at 26.04 in Q3 2023.
• A 5-year average of 698.64 and a median of 613.27 in 2020 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales tumbled 97.28% in 2022 and jumped 4970.03% in 2023, its largest moves.
• Over 5 years, Price to Sales stood at 761.14 in 2020, then slumped by 45.56% to 414.33 in 2021, then dropped by 4.45% to 395.87 in 2022, then soared by 203.53% to 1201.59 in 2023, then surged by 74.99% to 2102.64 in 2024.
• The last three Price to Sales figures came in at 2102.64 (Q2 2024), 200.06 (Q1 2024), and 1201.59 (Q4 2023), per Business Quant data.